--- https://www.ema.europa.eu/medicines/human/EPAR/Mysimba 2015 false false false United Kingdom French English treatment outcome syndication feed summary of product characteristics package leaflet drug evaluation drug combinations drug approval europe naltrexone naltrexone bupropion bupropion anti-obesity agents anti-obesity agents product surveillance, postmarketing adult overweight obesity overweight body mass index administration, oral Delayed-Action preparations appetite energy metabolism aged drug interactions pregnancy breast feeding drug evaluation, preclinical bupropion hydrochloride, naltrexone hydrochoride drug combination bupropion hydrochloride, naltrexone hydrochoride drug combination bupropion and naltrexone Product containing bupropion and naltrexone in oral dose form (medicinal product form) drug combinations drug combinations naltrexone bupropion